What Are Analysts Opinions On Apricus Biosciences, Inc. (APRI)


Apricus Biosciences, Inc. (APRI) will report its next earnings on May 31 AMC. The company reported the earnings of $-0.14/Share in the last quarter where the estimated EPS by analysts was $-0.12/share. The difference between the expected and actual EPS was $-0.02/share, which represents an Earnings surprise of -16.7%.

Many analysts are providing their Estimated Earnings analysis for Apricus Biosciences, Inc. and for the current quarter 2 analysts have projected that the stock could give an Average Earnings estimate of $-0.12/share. These analysts have also projected a Low Estimate of $-0.14/share and a High Estimate of $-0.1/share.

Some buy side analysts are also providing their Analysis on Apricus Biosciences, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

The Relative Volume of the company is 10.97 and Average Volume (3 months) is 944.38 million.

The company shows its Return on Assets (ROA) value of -132%. The Return on Equity (ROE) value stands at -186%.

While looking at the Stock’s Performance, Apricus Biosciences, Inc. currently shows a Weekly Performance of 75.3%, where Monthly Performance is 50%, Quarterly performance is -43.52%, 6 Months performance is -74.29% and yearly performance percentage is -58.33%. Year to Date performance value (YTD perf) value is -75.54%. The Stock currently has a Weekly Volatility of 23.21% and Monthly Volatility of 11.25%.